You are browsing the archive for 2012.
Determine the societal value for the treatment of rare diseases.
Create a priority-setting and decision making framework for expensive drugs for rare diseases.
Develop and initiate an ongoing research agenda related to policy and decision-making for expensive drugs for rare diseases.
Mentor future researchers and clinician scientists on the ethical, moral, clinical, legal, and policy and decision-making implications.
Develop and implement knowledge translation strategies that will facilitate the integration of evidence into policy making, and the evaluation of the decision-making framework, in the short and long-term.
European Commission – Press Release, June 07, 2012
Orphan medicines relate to diseases which affect not more than 5 persons in 10.000 in the EU. As a consequence, the economic potential of such medicines is very limited which hampers the development of new medicines. In response, the EU adopted dedicated legislation…..
Our team is proud to announce that our trainee, Shirin Rizzardo, is the recipient of 2012 Merck Canada Inc. Postgraduate Pharmacy Fellowship Award. Merck Canada annually awards this $15,000 Fellowship to a post-graduate pharmacy student attending a Canadian university, based on academic performance and publication credits. “This award is a phenomenal opportunity for me,” Shirin says….
The Globe and Mail, April 02, 2012
Nearly two dozen life insurers are banding together to share the risk of claims for expensive drugs, as costly new treatments for illnesses such as cancer and auto-immune diseases become more common. The problem is becoming more acute as medical research churns….
Business in Vancouver, March 20, 2012
From a sheer market perspective, Allon Therapeutics’ decision to focus on a rare a neurological disorder called progressive supranuclear palsy (PSP) doesn’t add up. After all, only 20,000 North Americans have the disease, compared with 4.4 million Alzheimer’s victims….
Dr. Lynd and his team of researchers recently received a $1,466,018 grant, over five years, through CIHR’s Emerging Team: Rare Diseases – Health Services Program.